Scientific Survey
Diabetes is a chronic condition that affects the way the body metabolizes glucose, leading to high blood sugar levels. Diabetes also puts an individual at risk for macrovascular and microvascular complications and usually manifest over a period of time
Recently, there have been introduction of multiple new therapies in diabetes management. The new therapies have been backed by good outcome trials that have demonstrated significant benefits in diabetes and various patient sub-groups
Additionally the robuse trials there have been facilitated guideline recommendations, which in turn that have prioritised the usage of some of these drugs. Further there have been approvals for additional indications like heart failure and chronic kidney disease even in the absence of diabetes for therapies approved first as anti-diabetic medications
This is very interesting as India has high incidence of diabetes, chronic kidney disease and heart failure coming independently and as co-morbidities of diabetes
This survey aimed at exploring the current perceptions, treatment choices and understanding of the newer therapeutic options thus enabling better positioning and communications to build greater usage with the right set of patients benefitting from the use of the right therapeutic options. The survey also enables understanding of the underlying need f0r scientific symposias and discussions at various national and regional meetings
The objective of the Survey:
1. To investigate the prevalence and severity of cardiovascular and renal morbidity in diabetic patients.
2. To evaluate the effectiveness of SGLT2 inhibitors and DPP4 inhibitors in managing cardiovascular and renal morbidity in diabetic patients.
3. To assess the safety and tolerability of SGLT2 inhibitors, DPP4 inhibitors and their FDCs in different sub group of patients
4. To gather feedback from leading endocrinologists regarding their experience with SGLT2 inhibitors and DPP4 inhibitors, including any adverse effects or benefits associated with these medications.
5. To understand the perceptions around newer therapies – finerenone, imeglimin and glp-1 receptor angonists
6. Evaluate the preference and usage insulin type
7. Assess the usage of Continuous glucose monitoring